Autonomic Nervous System Activity and the Risk of Nosocomial Infection in Critically Ill Patients With Brain Injury

Mathijs Wirtz (m.r.wirtz@amsterdamumc.nl)
Department of Intensive Care Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, and The Laboratory of Experimental Intensive Care and Anesthesiology of the Amsterdam University Medical Center, Amsterdam, The Netherlands. https://orcid.org/0000-0002-1923-083X

Jiri Moekotte
Amsterdam UMC - Locatie AMC: Amsterdam UMC Locatie AMC

Kirsten Balvers
Amsterdam UMC - Locatie AMC: Amsterdam UMC Locatie AMC

Marjolein Admiraal
Amsterdam UMC - Locatie AMC: Amsterdam UMC Locatie AMC

Jean-Francois Pittet
University of Alabama at Birmingham

Joe Colombo
Drexel University College of Medicine

Brant Wagener
University of Alabama at Birmingham

Carel Goslings
Amsterdam University Medical Centres: Amsterdam Universitair Medische Centra

Nicole Juffermans
Amsterdam UMC - Locatie AMC: Amsterdam UMC Locatie AMC

Research

Keywords: Autonomic nervous system, Brain injury, Immunosuppression, Nosocomial infection

DOI: https://doi.org/10.21203/rs.3.rs-94897/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Purpose:** Nosocomial infection contributes to adverse outcome after brain injury. This study investigates whether autonomic nervous system activity is associated with a decreased host immune response in patients following stroke or traumatic brain injury (TBI).

**Methods:** A prospective study was performed in adult patients with TBI or stroke who were admitted to the Intensive Care Unit of our tertiary university hospital between 2013 and 2016. Heart rate variability (HRV) was recorded daily and assessed for autonomic nervous system activity. Outcomes were nosocomial infections and immunosuppression, which was assessed *ex vivo* using whole blood stimulations with plasma of patients with infections, matched not-infected patients and healthy controls.

**Results:** Out of 64 brain injured patients, 23 (36%) developed an infection during their hospital stay. The ability of brain injured patients to generate a host response to LPS was diminished compared to healthy controls. Patients who developed an infection yielded significantly lower TNF-α and higher IL-10 values following *ex vivo* whole blood stimulations when compared to patients not developing an infection. This decreased host immune response was associated with altered admission HRV values. Brain-injured patients who developed an infection showed increased normalized high frequency power compared to patients not developing an infection, whereas normalized low frequency power was lower in infected patients.

**Conclusion:** Brain injured patients developing a nosocomial infection show parasympathetic predominance in the acute phase following brain injury, reflected by alterations in HRV, which parallels a decreased ability to generate an immune response to stimulation with LPS.

**Take-home Message**

Hyperactivity of the parasympathetic nervous system in the acute phase after brain injury seems to predispose patients to develop an infection due to a decreased systemic immunoresponsiveness. Whether high parasympathetic outflow, as reflected by the corresponding heart rate variability indices, might thus function as an early indicator of patients at risk for infection needs further investigation.

**Introduction**

Stroke and traumatic brain injury (TBI) result in high rates of infectious complications, with subsequent high mortality rates[1, 2]. Patients admitted to the intensive care unit (ICU) are vulnerable to nosocomial infection due to indwelling catheters and risk of aspiration with mechanical ventilation[3]. However these risk factors do not fully explain the disproportional higher infection rates in brain injured patients when compared to the general ICU population[1, 4, 5]. Brain injury mediated immunosuppression is a recognized clinical phenomenon in brain injured patients[2, 4, 5].
Following neurotrauma, a disruption in the well-balanced interplay between the nervous and immune system occurs within hours of the insult and can last for several weeks[6]. Cerebral inflammatory responses produce pro-inflammatory cytokines and an influx of immune cells, causing neural cell death and brain damage[7]. Possibly, this initial inflammatory burst exhausts the immune system causing peripheral immunosuppression. The mechanism by which this occurs is not fully understood, but activation of the autonomic nervous system may contribute to immunosuppression following brain injury[7, 8]. Heart rate variability (HRV) analysis, describing interval changes between successive heartbeats, provides information on autonomic nervous system activity and sympathovagal balance[9]. It represents a complex reflection of autonomic responsiveness of the cardiovascular system to changes in autonomic outflow. Increased parasympathetic nervous system activity correlates with immunosuppression and mortality in brain injured patients[10, 11]. This occurs through vagal nerve stimulation activating the cholinergic anti-inflammatory pathway, resulting in decreased systemic pro-inflammatory cytokine production, such as TNF-α[8].

This study aims to elucidate the role of the autonomic nervous system in infection risk following brain injury. We propose that parasympathetic surges may be a final common pathway in immunosuppression and that this may be associated with increased susceptibility to infection. We furthermore aim to elucidate temporal trends in autonomic nervous system activity along with patterns of inflammatory response profiles associated with brain injury mediated immunosuppression.

**Materials And Methods**

This prospective study was performed from March 2013 to July 2016 in our tertiary university hospital in the Netherlands.

**Population**

All patients ≥18 years old were eligible for inclusion if they suffered from TBI or stroke (ischemic or hemorrhagic) and required admission to the intensive care unit. Exclusion criteria comprised expected death within 1 hour of admission, burn or inhalation injury or emergency thoracotomy or cardiopulmonary resuscitation with chest compressions before ICU arrival. Patients with known pregnancy, receiving immunosuppressive medication prior to admission, with a known do-not-resuscitate order and patients already enrolled in a concurrent ongoing interventional randomized clinical trial were also excluded.

**Heart rate variability recordings**
Patients were hemodynamically monitored during their ICU or medium care stay as standard care. For HRV analysis, the heart rate of patients was recorded from the patient bedside monitor with specialized software from our hospital's technical department (HartRateMonitor3, Academic Medical Center, Amsterdam, The Netherlands). This software determines the position of the R peaks in the patient's electrocardiography at a sampling rate of 1000Hz. Ten minute epochs of the heart rate were recorded directly after admission and subsequently four times daily during the admission period at the ICU. Daily recorded 10 minute epochs were pooled together to calculate a daily mean.

**Blood samples**

Blood samples were collected on admission day and 24 and 72 hours thereafter (days 0, 1 and 3). The tubes were centrifuged for 10 minutes at 1750 relative centrifugal force (RCF) and 18˚C. The upper two-thirds of the plasma was centrifuged again to obtain platelet-free plasma and stored as 250 µL aliquots at -80˚C.

**Definition of infection**

Infection criteria were adopted from the MARS project (Molecular Diagnosis and Risk Stratification of Sepsis)[12], which has provided criteria for infection classification that were modified from the Centers for Disease Control (CDC) and International Sepsis Forum (ISF) criteria. All available clinical, microbiological, and radiological evidence on infections was collected. Infections were scored for infection source and certainty of diagnosis resulting in definite, probable and possible infections. The MARS criteria for infections can be found in the online additional file.

**Antibiotic management**

Selective digestive tract decontamination (SDD), consisting of parenteral and enteral antimicrobials, was administered to patients with an expected ICU stay of >3 days. This includes a 4 day regime of intravenous cefotaxime. Also, an enteral nonabsorbable suspension containing polymyxin, tobramycin and amphotericin B was administered through a nasogastric tube 4 times a day. Orabase paste was applied 4 times a day to the oropharyngeal mucosa. Furthermore antibiotics chosen based on local protocol and expert opinion were started empirically when infection was suspected.

**Whole blood stimulation**

Whole blood stimulations were performed as described before[13]. Briefly, heparin-anticoagulated blood from a healthy volunteer was collected. 500 µL whole blood samples were diluted in a 1:1 ratio with RPMI (Roswell Park Memorial Institute, Buffalo, USA), supplemented with glutamine 0.3 g/L and lipopolysaccharide (LPS E.coli; O111:B4 Ultrapure SIGMA, 1 ng/ml). Subsequently, 100 µL of plasma
from either infected or non-infected patients was added. Whole blood stimulated with LPS without the addition of patient plasma served as a positive control. Whole blood buffered with RPMI without the addition of patient plasma or LPS served as a negative control. The samples were then incubated for 24 hours at 5% CO₂ at 37°C. After incubation, the samples were centrifuged (1200 RCF at 18°C for 10 minutes) and the upper two-thirds of the plasma was collected and stored at -20°C.

ELISA

TNF-α and IL-10 levels were measured in the supernatant collected after the whole blood stimulations by enzyme-linked immunosorbent assays (ELISA) according to the manufacturer’s instructions (R&D Systems, Abingdon, United Kingdom).

Outcome

Primary outcome was nosocomial infection and the extent of immunosuppression, defined as the outcome of ex vivo whole blood stimulations. Secondary outcomes included heart rate variability, duration of ventilation, length of hospital and ICU stay and 28-day mortality.

Statistical analyses

HRV recordings were analyzed with HRV algorithms in MATLAB software (MathWorks, Natick, USA) adhering to international standards[14]. The rationale behind the algorithms is described in more detail in the online additional file. Normalized units of high-frequency power (HFnu) as a reflection of parasympathetic activity and normalized units of low-frequency power (LFnu) as a reflection of sympathetic activation were used to assess autonomic activity[14]. Also low-frequency:high-frequency (LF:HF) ratio was analyzed, as this ratio is considered to reflect either the sympathovagal balance or sympathetic nervous system activity[10].

All patients with definite or probable infections were selected for ex vivo whole blood stimulation tests. These patients were compared to non-infected patients, matched for age and APACHE II scores.

Distribution of variables was examined for normality using the Kolmogorov-Smirnov test. Continuous variables are expressed as mean and standard deviation (SD) or median and interquartile range (IQR) and were analyzed using the Student's t-test or the Mann-Whitney U test, depending on the distribution. Categorical factors are expressed as proportions and were analyzed by chi-square testing. Testing between infected patients, non-infected patients and controls in ex vivo whole blood stimulation tests was done with the one-way ANOVA test. P-values less than 0.05 were considered statistically significant.

Results
A total of 64 brain injured patients were included. Patient demographics and baseline characteristics are displayed in Table 1. Patients were 51±19 years old and 73% were male. 50 patients (78%) suffered from TBI (with or without subsequent hemorrhagic stroke), 9 patients (14%) from ischemic stroke and 5 patients (8%) were admitted with hemorrhagic stroke. Median GCS was 7 on emergency department admission and patients were critically ill and severely injured, as reflected by a median APACHE-II score of 19 and a mean ISS score of 24.

Infections

Baseline characteristics between patients who did and did not develop an infection were similar, with the exception of hemoglobin levels being lower in infected patients (Table 1). The type and probability of infections among included patients are presented in supplemental Table 1. A total of 23 patients (36%) developed at least 1 infection during their hospital stay. Infections in 8 patients were classified as definite, in 5 patients as probable and in 10 as possible. The total number of infections was 28, as 4 patients developed multiple infections. Pneumonia was most frequently observed (n=16), followed by urinary tract infections (n=4) and intracranial infections (n=4). Other observed infections include primary blood stream infections and surgical site infections. Two-thirds of infected patients developed an infection during their initial ICU stay, while the others developed an infection after transfer to the ward. Staphylococcus aureus was most frequently cultured (25%, Figure 1). Patients who developed an infection did so after a median of 6 days (IQR 3-12) after admission. More invasive procedures were performed in infected patients compared to patients not developing an infection (see Table 2). No difference was seen in the use or duration of antibiotic treatment. Prehospital use of beta-blockers was also similar (15 vs 15%, p=0.80), as was its use at the day of admission to the ICU (5 vs 9%, p=0.55).

Cytokine production after whole blood stimulation

Cytokine production in response to ex vivo stimulation with LPS was measured in 12 patients with definite or probable infections and compared to non-infected matched controls as well as healthy controls (see Figure 2). Brain injured patients had a significant lower ability to generate TNF-α and IL-10 production when compared to healthy controls (all p<0.001). On admission to the ICU, patients that developed an infection during their hospital stay had lower TNF-α production in response to LPS compared to non-infected patients (86 vs 192 pg/mL, p=0.030). This difference was also apparent three days after admission (113 vs 287 pg/mL, p=0.024).

Production of the anti-inflammatory cytokine IL-10 was also mitigated for all brain injured patients during their stay in the ICU when compared to healthy controls (all p<0.001). However, compared to patients without an infection, a trend towards higher values at baseline was found in infected patients (122 vs 84 pg/mL, p=0.071).
Heart rate variability

Results of heart rate variability analysis of the acute phase following admission after brain injury are shown in supplemental Table 2. At ICU admission, patients who acquired an infection later during their hospital stay had significantly lower normalized low frequency power (LFnu, 0.46 vs 0.64, p=0.033) accompanied with higher normalized high frequency power (HFnu, 0.54 vs 0.36, p=0.033) when compared to patients who did not acquire an infection. Furthermore, a trend was found towards a lower LF:HF ratio in infected patients compared to non-infected patients (0.93 vs 1.82, p=0.065).

Figure 3 shows the longitudinal patterns of HRV after brain injury. Following the acute phase, patients not developing an infection showed a decrease in LFnu and LF:HF and an increase in HFnu in the first 24 hours, while these values remained stable in patients who later developed an infection. After 24 hours, there was no significant difference anymore between the groups. Patients developing an infection during their stay in the hospital had a median LF:HF ratio below reference values of healthy volunteers, as well as a higher HFnu in the first 24 hours after admission to the ICU. Patients without an infection showed values within these reference ranges.

Outcome

Duration of mechanical ventilation was significantly longer in patients who developed an infection compared to those who did not (6 vs 2 days, p=0.042). More often, these patients required use of vasopressors (74 vs 44%, p=0.021) and required these for a longer time period (1 vs 0 day, p=0.016). Also, hospital length of stay was significantly prolonged when patients developed an infection (24 vs 9 days, p=0.001), as was ICU stay (8 vs 4 days, p=0.011). However, 28-day mortality rates did not differ between infected and non-infected patients (17 vs 19%, p=0.835, see Table 2).

Discussion

Brain injured patients had a decreased ability to generate an immune response to bacterial LPS stimulation \textit{ex vivo} compared to healthy controls. Infections were found in 36% of patients, associated with a parasympathetic surge at ICU admission and reduced immunoresponsiveness in the first 3 days of ICU admission, reflected by decreased TNF-\(\alpha\) values after \textit{ex vivo} bacterial stimulation. At 72 hours after injury, parasympathetic activity decreased, whereas TNF-\(\alpha\) production in response to a bacterial stimulus remained abrogated.

Despite the fact that 75% of patients received antibiotic treatment during their ICU stay, with 53% already starting on admission, 36% of patients developed an infection during their hospital stay. This incidence is similar to findings in previous studies[1, 2]. Of note, most pathogens found in positive microbiology cultures in infected patients in our study were covered by SDD prophylaxis. Also, the number of patients receiving antibiotic treatment did not differ between patients developing an infection and those who did not, even after correcting for the use of SDD. This shows that antibiotic (prophylactic) treatment may not
effectively prevent infections in these patients. In brain injury patients, evidence for the use of prophylactic antibiotics is scarce and somewhat conflicting, with most studies showing no effect of prophylactic antibiotics in preventing pneumonia[4, 15].

Significant autonomic regulation dysfunction in brain injured patients has been reported, with lower levels of overall HRV when compared to healthy controls[10, 16]. Our data demonstrate an autonomic shift towards parasympathetic dominance preceding the occurrence of infection, reflected by higher HFnu values. This parasympathetic surge corroborated with a systemic immune suppression as reflected by a decreased ability to generate TNF-α in ex vivo stimulated plasma samples. Previously published data confirmed that parasympathetic activity correlated strongly with lower plasma TNF-α levels[10]. Thereby parasympathetic activity may up-regulate the brain’s immune system at the expense of the body’s immune system, as was shown in septic trauma patients[17]. Also, it has been shown that brain injury leads to increased activity of vagal nerve parasympathetic fibers, which in turn leads to downregulation of TNF-α production through the cholinergic pathway without affecting IL-10 production[18]. What is more, a study evaluating HRV in the acute phase after ischemic stroke found that increased vagal activity (increased HFnu) was predictive of the development of subacute infections[19].

Patients developing an infection during their hospital stay required significantly more invasive procedures, as well as longer vasopressor use, days of mechanical ventilation and ICU length of stay. However, as patients showed a parasympathetic surge along with immunosuppression on admittance to the ICU, we believe invasive procedures are a consequence of the infection, rather than the cause. This is underlined by the fact that 77% of procedures were performed after the infection was diagnosed.

Our findings may have potential clinical consequences. HRV, in particular HFnu, may distinguish patients at risk of acquiring an infection and serve as an indicator to initiate therapy. Several potential therapies intervening in autonomic regulation have been described. Trials on counteracting autonomic nervous system activity by beta-blockade show conflicting results[20-22]. A recent systematic review in TBI patients showed that infections occurred more often in patients receiving beta-blockade[23]. In our study, total in-hospital administration of beta-blockers was similar between infected and non-infected patients, although a trend towards more and longer beta-blocker use was found in patients who developed an infection. The use of beta-blocking agents may result in higher parasympathetic activity, as measured by HRV[24]. In our study parasympathetic hyperactivity preceding development of an infection and was not related to beta-blocker administration. Thereby, our results do not support the use of beta-blockers in brain injured patients already in a parasympathetic hyperactive state at admission to the ICU.

Several therapies targeting the cholinergic pathway have also been suggested in brain injury patients[25]. Research with animal models demonstrated that inhibition of cholinergic signaling, by vagotomy or by using acetylcholine-receptor-deficient mice, enabled reversal of the observed immune hyporesponsiveness and prevented pneumonia after stroke[26]. Preclinical studies investigating the administration of muscarinic- and nicotinic-acetylcholine-receptor-antagonists showed a benefit in neural survival by preventing the effects of acute elevation of acetylcholine in parasympathetic hyperactivation.
What is more, pharmacological inhibition of the nicotinic-acetylcholine-receptor reduced lung injury and mortality in mice with a post-stroke pneumonia[27]. However, the effect of these agents needs further research, specifically focusing on the effect of these agents on the parasympathetic surge in the acute phase after brain injury and the relation with immune functioning and infection rates.

**Limitations**

We did not retain raw electrocardiography data, nor did we record respiratory variability, rendering it more difficult to isolate the parasympathetic activity signal from the sympathetic activity signal[28]. Also, only explorative analysis could be performed without correcting for multiple comparisons given our small cohort. For the same reason no subgroup analysis of TBI and stroke patients could be performed. Therefore, heterogeneity may have influenced our results. Lastly, the use of HRV has some drawbacks. Due to the large heterogeneity and poor description of the methodology of studies using HRV analysis and the lack of a uniform protocol for its effectuation, comparisons with contemporary literature may be hampered.

**Conclusion**

Infection occurs frequently after brain injury. Hyperactivity of the parasympathetic nervous system in the acute phase after injury may predispose patients to the development of an infection, due to a decreased systemic immunoresponsiveness. Whether high parasympathetic outflow, as reflected by the corresponding HRV indices, might thus function as an early indicator of patients at risk for infection needs further investigation. Results of this study may stimulate research aiming at improving the autonomic balance in order to reduce infection rates.

**Declarations**

**Funding:** not applicable.

**Conflicts of interest/Competing interests:** Prof. Colombo was medical director and part-owner of Ansar Medical technologies, Inc. when this study was performed. Dr. Wagener and Prof. Pittet received a grant from NIGMS during the conduct of the study.

**Ethics approval:** This study was performed with approval of the ethics committee of the Amsterdam University Medical Centers. The study was conducted according to the principles of the Declaration of Helsinki and adhering to good clinical practice guidelines and the Medical Research Involving Human Subjects Act (WMO).

**Consent to participate:** Written informed consent was obtained from a legal representative or from the patient in case the patient was deemed awake and adequate.

**Consent for publication:** All patients and participants to the study gave their consent for publication.
Availability of data and material: The data that support the findings of this study are available from the corresponding author, MW, upon reasonable request.

Code availability: not applicable

Authors’ contributions: Study concept and design: NJ, JC, JG, BW, JP; Acquisition, analysis, or interpretation of data: MW, JM, KB; Drafting of the manuscript: MW, JM; Critical revision of the manuscript for important intellectual content: MW, JM, KB, MA, JP, JC, BW, JG, NJ; Statistical analysis: MW, JM, MA, NP.

Acknowledgements

None.

References

1. Emsley HC, Hopkins SJ: Acute ischaemic stroke and infection: recent and emerging concepts. The Lancet Neurology 2008, 7: 341-353
2. Busl KM: Nosocomial Infections in the Neurointensive Care Unit. Neurosurgery clinics of North America 2018, 29: 299-314
3. Wastfelt M, Cao Y, Strom JO: Predictors of post-stroke fever and infections: a systematic review and meta-analysis. BMC neurology 2018, 18: 49
4. Vermeij JD, Westendorp WF, Dippel DW, van de Beek D, Nederkoorn PJ: Antibiotic therapy for preventing infections in people with acute stroke. The Cochrane database of systematic reviews 2018, 1: Cd008530
5. Hoffmann S, Harms H, Ulm L, Nabavi DG, Mackert BM, Schmehl I, Jungehulsing GJ, Montaner J, Bustamante A, Hermans M, Hamilton F, Gohler J, Malzahn U, Malsch C, Heuschmann PU, Meisel C, Meisel A: Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia - The PREDICT study. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2017, 37: 3671-3682
6. Prass K, Meisel C, Hoflich C, Braun J, Halle E, Wolf T, Ruscher K, Victorov IV, Priller J, Dimagl U, Volk HD, Meisel A: Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. The Journal of experimental medicine 2003, 198: 725-736
7. Shim R, Wong CH: Ischemia, Immunosuppression and Infection—Tackling the Predicaments of Post-Stroke Complications. International journal of molecular sciences 2016, 17
8. Santos Samary C, Pelosi P, Leme Silva P, Rieken Macedo Rocco P: Immunomodulation after ischemic stroke: potential mechanisms and implications for therapy. Critical care (London, England) 2016, 20: 391
9. Buchman TG, Stein PK, Goldstein B: Heart rate variability in critical illness and critical care. Current opinion in critical care 2002, 8: 311-315

10. Kox M, Vrouwenvelder MQ, Pompe JC, van der Hoeven JG, Pickkers P, Hoedemaekers CW: The effects of brain injury on heart rate variability and the innate immune response in critically ill patients. Journal of neurotrauma 2012, 29: 747-755

11. Colombo J, Shoemaker WC, Belzberg H, Hatzakis G, Fathizadeh P, Demetriades D: Noninvasive monitoring of the autonomic nervous system and hemodynamics of patients with blunt and penetrating trauma. The Journal of trauma 2008, 65: 1364-1373

12. van Vught LA, Klein Klouwenberg PM, Spitoni C, Scicluna BP, Wiewel MA, Horn J, Schultz MJ, Nurnberg P, Bonten MJ, Cremer OL, van der Poll T: Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis. Jama 2016, 315: 1469-1479

13. Balvers K, Curry N, Kleinveld DJ, Boing AN, Nieuwland R, Goslings JC, Juffermans NP: Endogenous microparticles drive the proinflammatory host immune response in severely injured trauma patients. Shock (Augusta, Ga) 2015, 43: 317-321

14. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996, 93: 1043-1065

15. Poole D, Chieregato A, Langer M, Viaggi B, Cingolani E, Malacarne P, Mengoli F, Nardi G, Nascimben E, Riccioni L, Turriziani I, Volpi A, Coniglio C, Gordini G: Systematic review of the literature and evidence-based recommendations for antibiotic prophylaxis in trauma: results from an Italian consensus of experts. PloS one 2014, 9: e113676

16. Lees T, Shad-Kaneez F, Simpson AM, Nassif NT, Lin Y, Lal S: Heart Rate Variability as a Biomarker for Predicting Stroke, Post-stroke Complications and Functionality. Biomarker insights 2018, 13: 1177271918786931

17. Hatzakis GB, H.; Shoemaker, W.; Colombo, J.; Demetriades. D.: Noninvasive Autonomic and Hemodynamic Monitoring in Severe Sepsis. J Clin Anesth Pain Med 2017, 1

18. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405: 458-462

19. Gunther A, Salzmann I, Nowack S, Schwab M, Surber R, Hoyer H, Witte OW, Hoyer D: Heart rate variability - a potential early marker of sub-acute post-stroke infections. Acta neurologica Scandinavica 2012, 126: 189-196

20. Sykora M, Siarnik P, Diedler J: beta-Blockers, Pneumonia, and Outcome After Ischemic Stroke: Evidence From Virtual International Stroke Trials Archive. Stroke 2015, 46: 1269-1274

21. Maier IL, Becker JC, Leyhe JR, Schnieder M, Behme D, Psychogios MN, Liman J: Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression. PloS one 2018, 13: e0196174
22. Starr JB, Tirschwell DL, Becker KJ: Increased infections with beta-blocker use in ischemic stroke, a beta2-receptor mediated process? Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2017, 38: 967-974

23. Chen Z, Tang L, Xu X, Wei X, Wen L, Xie Q: Therapeutic effect of beta-blocker in patients with traumatic brain injury: A systematic review and meta-analysis. Journal of critical care 2017, 41: 240-246

24. Aboab J, Mayaud L, Sebille V, de Oliveira R, Jourdain M, Annane D: Esmolol indirectly stimulates vagal nerve activity in endotoxemic pigs. Intensive care medicine experimental 2018, 6: 14

25. Shin SS, Dixon CE: Alterations in Cholinergic Pathways and Therapeutic Strategies Targeting Cholinergic System after Traumatic Brain Injury. Journal of neurotrauma 2015, 32: 1429-1440

26. Engel O, Akyuz L, da Costa Goncalves AC, Winek K, Dames C, Thielke M, Herold S, Bottcher C, Priller J, Volk HD, Dirnagl U, Meisel C, Meisel A: Cholinergic Pathway Suppresses Pulmonary Innate Immunity Facilitating Pneumonia After Stroke. Stroke 2015, 46: 3232-3240

27. Lafargue M, Xu L, Carles M, Serve E, Anjum N, Iles KE, Xiong X, Giffard R, Pittet JF: Stroke-induced activation of the alpha7 nicotinic receptor increases Pseudomonas aeruginosa lung injury. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2012, 26: 2919-2929

28. Aysin B, Aysin E: Effect of respiration in heart rate variability (HRV) analysis. Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference 2006, 1: 1776-1779

Tables
Table 1. Baseline characteristics of brain-injured patients

| Main characteristics | All patients (n=64) | Infected (n=23) | Non-infected (n=41) |
|----------------------|--------------------|----------------|---------------------|
| Age (years, n, %)    | 51 (19.3)          | 52 (18.2)      | 50 (20.1)           |
| Male gender (n, %)   | 47 (73%)           | 15 (65%)       | 32 (78%)            |
| Reason for ICU admission (n, %) |        |                |                     |
| TBI                  | 50 (78%)           | 18 (78%)       | 32 (78%)            |
| iCVA                 | 9 (14%)            | 2 (9%)         | 7 (17%)             |
| hCVA                 | 5 (8%)             | 3 (13%)        | 2 (5%)              |
| Admission injury/illness severity scores |        |                |                     |
| ISS (mean, SD)       | 24 (11)            | 26 (12)        | 23 (11)             |
| GCS (median, IQR)    | 7 (3-9)            | 7 (3-8)        | 6 (3-9)             |
| SAPS 2 (mean, SD)    | 43.7 (11.3)        | 45.5 (9.3)     | 42.7 (12.3)         |
| APACHE 2 (median, IQR) | 19 (16-23)        | 19 (17-21)     | 19 (15-23)          |
| Comorbidity          |                    |                |                     |
| Prehospital beta blocker use (n, %) | 10 (16%)          | 4 (17%)        | 6 (15%)             |
| Hypertension (n, %)  | 14 (22%)           | 5 (22%)        | 9 (22%)             |
| CVA (n, %)           | 6 (9%)             | 3 (13%)        | 3 (7%)              |
| Cardiac pathology (n, %) | 11 (17%)          | 3 (13%)        | 8 (20%)             |
| Diabetes mellitus (n, %) | 6 (9%)            | 2 (9%)         | 4 (10%)             |
| COPD (n, %)          | 4 (6%)             | 1 (4%)         | 3 (7%)              |
| Alcohol abuse (n, %) | 5 (8%)             | 2 (9%)         | 3 (7%)              |
| Admission clinical parameters |        |                |                     |
| Heart rate (bpm, mean, SD) | 80 (17)          | 83 (15)        | 79 (18)             |
| SBP (mmHg, mean, SD) | 132 (29)          | 132 (37)       | 133 (24)            |
| Temperature (°C, mean, SD) | 35.6 (1.2)      | 35.5 (1.3)     | 35.7 (1.2)          |
| Admission lab parameters |        |                |                     |
| Hb (mmol/l, median, IQR) | 7.9 (6.7-8.5)    | 7.2 (6.3-8.2)* | 8.0 (7.5-8.8)       |
| WCC (× 10^9/l, mean SD) | 11.8 (4.7)       | 11.6 (5.8)     | 11.9 (4.0)          |
**CRP (mg/l, median, IQR)**

|        |        |        |        |
|--------|--------|--------|--------|
| 3.8    | 0.7-6.7| 3.8    | 2-7.4  |
| 4.9    | 0.6-7.8|        |        |

Data are presented as mean standard deviation, median and interquartile range or absolute number and percentage.

ICU, intensive care unit; TBI, traumatic brain injury; iCVA, ischemic cerebrovascular accident; hCVA, hemorrhagic cerebrovascular accident; ISS, injury severity score; GCS, Glasgow Coma Score; SOFA, sequential organ failure assessment score; SAPS 2, simplified acute physiology score 2; APACHE 2, acute physiology and chronic health evaluation 2 score; MI, myocardial infarction; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure, Hb, hemoglobin, WCC, white cell count; CRP, C-reactive protein.

†Cardiac pathology includes MI and AF, as well as cardiac valve pathology and other (paroxysmal) rhythm disorders.

*Significantly different from non-infected group.*
Table 2. Treatment on ICU and outcome

|                                      | All patients (n=64) | Infected (n=23) | Non-infected (n=41) | p-value |
|--------------------------------------|---------------------|-----------------|---------------------|---------|
| **Invasive procedures**               |                     |                 |                     |         |
| Surgery (n, %)                        | 38 (59)             | 17 (74)         | 21 (51)             | 0.076   |
| Amount of surgical procedures (n, median, IQR) | 1 (0-1)             | 1 (0-3)         | 1 (0-1)             | **0.006** |
| Tracheostomy (n, %)                   | 10 (16)             | 8 (35)          | 2 (5)               | **0.002** |
| Intracranial device (n, %)            | 20 (31)             | 12 (52)         | 8 (20)              | **0.007** |
| Duration of Intracranial device (days, median, IQR) | 0 (0-2)             | 1 (0-6)         | 0 (0-0)             | **0.005** |
| Central venous catheter (n, %)        | 26 (41)             | 12 (52)         | 14 (34)             | 0.159   |
| Duration of Central venous catheter (days, median, IQR) | 0 (0-5)             | 2 (0-8)         | 0 (0-3)             | 0.103   |
| **Treatment during ICU/CMC stay**     |                     |                 |                     |         |
| Antibiotics (n, %)                    | 48 (75)             | 19 (83)         | 29 (71)             | 0.292   |
| SDD (n, %)                            | 44 (69)             | 18 (78)         | 26 (63)             | 0.219   |
| Other than SDD (n, %)                 | 37 (58)             | 16 (70)         | 21 (51)             | 0.154   |
| Duration of antibiotics (days, median, IQR) | 5 (1-7)             | 5 (2-9)         | 4 (0-7)             | 0.126   |
| Vasopressor (n, %)                    | 35 (55)             | 17 (74)         | 18 (44)             | **0.021** |
| Duration of vasopressor use (days, median, IQR) | 1 (0-2)             | 1 (0-5)         | 0 (0-2)             | **0.016** |
| Beta blocker (n, %)                   | 12 (19)             | 7 (30)          | 5 (12)              | 0.073   |
| Duration of Beta blocker use (days, median, IQR) | 0 (0-0)             | 0 (0-2)         | 0 (0-0)             | 0.066   |
| Mechanically ventilated (n, %)        | 61 (95)             | 23 (100)        | 38 (93)             | 0.184   |
| Duration of ventilation (days, median, IQR) | 3 (2-7)             | 6 (2-11)        | 2 (2-5)             | **0.042** |
| **Outcome**                           |                     |                 |                     |         |
| Onset of (first) infection (days, median, IQR) | NA                  | 6 (3-12)        | NA                  | NA      |
| ICU stay (days, median, IQR)          | 4.5 (3-9)           | 8 (3-14)        | 4 (2-6.5)           | **0.011** |
| Total length of hospital stay (days, median, IQR) | 12 (6-26)           | 24 (10-44)      | 9 (5-17)            | **0.001** |
| Discharge location (n, %) | Home | Another hospital | Nursing home | p-value |
|--------------------------|------|-----------------|--------------|---------|
|                           | 20 (31) | 4 (17) | 16 (39) | 0.073  |
|                           | 17 (27) | 8 (35) | 10 (24) | 0.375  |
|                           | 14 (22) | 7 (30) | 7 (17)  | 0.215  |
| 28-day mortality (n, %)  | All causes | 12 (19) | 4 (17) | 8 (19) | 0.835  |
|                           | Brain injury | 10 (8) | 3 (13) | 7 (16) | 0.670  |
|                           | MOF | 2 (3) | 1 (4) | 1 (2) | 0.674  |

Data are presented as median and interquartile range or absolute number and percentage.
SDD, selective decontamination of the digestive tract; ICU, intensive care unit.

Figures

[Diagram showing bacterial distribution]
Figure 1

Two-thirds of infected patients developed an infection during their initial ICU stay, while the others developed an infection after transfer to the ward. Staphylococcus aureus was most frequently cultured (25%, Figure 1).

Figure 2

Cytokine production in response to ex vivo stimulation with LPS was measured in 12 patients with definite or probable infections and compared to non-infected matched controls as well as healthy controls (see Figure 2).
Figure 3 shows the longitudinal patterns of HRV after brain injury. Following the acute phase, patients not developing an infection showed a decrease in LFnu and LF:HF and an increase in HFnu in the first 24 hours, while these values remained stable in patients who later developed an infection.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile.docx